PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23216663-9 2014 Patients with SCC had a higher cumulative dose of azathioprine (>= 500 g: OR 30.0 [95% CI 2.6-345.1]) and longer treatment duration (>= 11 years: OR 13.5 [95% CI 1.3-143.6]). Azathioprine 50-62 serpin family B member 3 Homo sapiens 14-17 27163483-5 2016 The overall summary estimate showed a significantly increased risk of SCC in relation to azathioprine exposure (1.56, 95% confidence interval [CI] 1.11-2.18). Azathioprine 89-101 serpin family B member 3 Homo sapiens 70-73 27163483-8 2016 The pooled findings of available evidence support the contention that treatment with azathioprine increases the risk of SCC in OTRs. Azathioprine 85-97 serpin family B member 3 Homo sapiens 120-123 28099404-9 2017 Fair skin type, multiple tumors before retransplantation, treatment with azathioprine, T cell-depleting antibodies, and delayed revision of immunosuppression were associated with an increased risk of aggressive cutaneous SCC after retransplantation. Azathioprine 73-85 serpin family B member 3 Homo sapiens 221-224 23216663-11 2014 CONCLUSIONS: In this cohort of patients with AIRD treated with azathioprine for at least 1 year, the risk of SCC was increased, as compared with the general population. Azathioprine 63-75 serpin family B member 3 Homo sapiens 109-112 23223314-1 2013 BACKGROUND: Conversion to sirolimus from calcineurin inhibitor- (CNI), azathioprine- (AZA) and mycophenolate-based regimens reduces the risk of development of squamous cell carcinoma of the skin (SCC) in kidney transplant recipients (KTRs). Azathioprine 71-83 serpin family B member 3 Homo sapiens 196-199 23223314-1 2013 BACKGROUND: Conversion to sirolimus from calcineurin inhibitor- (CNI), azathioprine- (AZA) and mycophenolate-based regimens reduces the risk of development of squamous cell carcinoma of the skin (SCC) in kidney transplant recipients (KTRs). Azathioprine 86-89 serpin family B member 3 Homo sapiens 196-199 17454960-1 2007 Immunosuppressive therapy with azathioprine has been documented to cause squamous cell carcinoma (SCC) at various sites. Azathioprine 31-43 serpin family B member 3 Homo sapiens 98-101 20970593-11 2010 Different immunosuppressive agents have different risks of nonmelanoma skin cancer, as AZA increases the risk of SCC and MMF is a protective factor. Azathioprine 87-90 serpin family B member 3 Homo sapiens 113-116 17454960-2 2007 We report possibly the first case of SCC of the kidney in a young male who received azathioprine for a long time. Azathioprine 84-96 serpin family B member 3 Homo sapiens 37-40 15381547-6 2004 RESULTS: The cumulative immunosuppressive drug dose 3 years after transplantation (calculated by a weighted linear combination of azathioprine, cyclosporine, and corticosteroid cumulative doses [WLC]) was independently associated with an increased risk of developing SCC but not BCC. Azathioprine 130-142 serpin family B member 3 Homo sapiens 267-270 15687239-5 2005 Major risk factors for the development of SCC were long duration of chronic GVHD therapy (P < .001); use of azathioprine, particularly when combined with cyclosporine and steroids (P < .001); and severe chronic GVHD (P = .004). Azathioprine 111-123 serpin family B member 3 Homo sapiens 42-45 15687239-7 2005 Additional analyses determined that prolonged immunosuppressive therapy and azathioprine use were also significant risk factors for SCC of the skin and of the oral mucosa. Azathioprine 76-88 serpin family B member 3 Homo sapiens 132-135 10025742-5 1999 After adjustment for age, kidney transplant recipients receiving cyclosporine, azathioprine, and prednisolone had a significantly (2.8 times) higher risk of cutaneous SCC relative to those receiving azathioprine and prednisolone. Azathioprine 79-91 serpin family B member 3 Homo sapiens 167-170